BFEC
BHVN

Benjamin F. Edwards & Company’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Benjamin F. Edwards & Company’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$15K – 1817
2020
Q2 		$15K Hold
200
– – ﹤0.01% 1199
2020
Q1 		$7K Buy
+200
New +$9.14K ﹤0.01% 1385

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Benjamin F. Edwards & Company's BHVN Position: Q3 2020 in Review

Benjamin F. Edwards & Company sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2020, closing a stake of 200 shares — an estimated $15K sold.

Benjamin F. Edwards & Company first reported a position in BHVN in Q1 2020 and held it in 2 quarters. The position peaked at $15K in Q2 2020. 215 funds tracked by Wall St. Rank hold BHVN as of Q3 2020.

  • Benjamin F. Edwards & Company reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2020 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 200 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2020, an estimated $15K.
  • Benjamin F. Edwards & Company first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2020 and held it in 2 quarters.
  • Benjamin F. Edwards & Company's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $15K in Q2 2020.
  • 215 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2020.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2020, filed 13 Nov 2020.